Magnus Jaderberg
Chief Tech/Sci/R&D Officer en Targovax Oy .
Perfil
Magnus Jaderberg is currently working as a Principal at Karolinska Institutet, an Honorary Lecturer at King's College (Pennsylvania), a Principal at The Royal College of Physicians, and as the Chief Medical Officer at Targovax Oy.
Previously, he worked as the Chief Medical Officer-Europe at Bristol Myers Squibb Co. and as the Chief Medical Officer at Circio Holding ASA.
Cargos activos de Magnus Jaderberg
| Empresas | Cargo | Inicio |
|---|---|---|
Targovax Oy
 Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | Chief Tech/Sci/R&D Officer | - |
| King's College (Pennsylvania) | Corporate Officer/Principal | - |
| Karolinska Institutet | Corporate Officer/Principal | - |
| The Royal College of Physicians | Corporate Officer/Principal | - |
Antiguos cargos conocidos de Magnus Jaderberg.
| Empresas | Cargo | Fin |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
| CIRCIO HOLDING ASA | Chief Tech/Sci/R&D Officer | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| CIRCIO HOLDING ASA | Health Technology |
| Empresas privadas | 1 |
|---|---|
Targovax Oy
Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | Health Technology |
- Bolsa de valores
- Insiders
- Magnus Jaderberg
